Skip to content

ABG Oxidative Stress Study Protocol-1

Proof of Concept Study to Evaluate the Effect of Oxidative Stress Response of Plant Concentrate Blends in Healthy Men

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02213523
Enrollment
60
Registered
2014-08-11
Start date
2012-09-30
Completion date
2013-12-31
Last updated
2014-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

antioxidant

Brief summary

This is a proof of concept study that evaluates the response to oxidative stress in healthy men after taking plant concentrates.

Detailed description

Sustained oxidative stress may cause hypertension, insulin resistance, metabolic syndrome, cardiovascular disease and other chronic conditions. Diets rich in natural antioxidants is associated with protective effects on the investigators health. The strategy to prevent chronic disease development and in making up the nutritional gap in the investigators diet has shifted from vitamins and minerals supplementation to whole foods and whole food products. The objectives is to evaluate the effect of oxidative stress response of plant concentrate blends. Also, we'll confirm that vitamins, minerals and plant concentrates will not influence the biomarker expression that were monitored in the oxidative stress biomarkers. Lastly, collecting additional information on whether blends of plant concentrate have other potential health benefits. This study will test the dose-response of blends of plant concentrates. Healthy men (n=60) with low fruit and vegetable intake will participate in a 32 day or 46 days. Each treatment duration lasts 14 days. Microarray assay and real time-polymerase chain reaction will be performed.Genes associated with oxidative stress will me monitored. The outcome of this study will help us understand how to design and develop future antioxidant related products.

Interventions

DIETARY_SUPPLEMENTPlant concentrate A

Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.

DIETARY_SUPPLEMENTPlant concentrate B

Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.

DIETARY_SUPPLEMENTPlant concentrate C

Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.

DIETARY_SUPPLEMENTPlant concentrate D

Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.

Sponsors

Access Business Group
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
MALE
Age
45 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy adult men between 45-65 yr old with low fruit and vegetable intake * Individual with low fruit and vegetable intake and consuming fewer than 12 items found on the Recommended Foods Check (RFC) (AppendixI) per week. (score \<12 pts) * Individuals with screening blood and urine laboratory values within 20% of normal range indicated in the lab report (Appendix IV) * Individual should be judged to be in good general health on the basis of an interview and abbreviated physical exam. * Individual understands the procedures and agrees to participate in the study. * Individual is willing to maintain their exercise habits and dietary pattern throughout the duration of the trial. * Individual is willing to consume a diet or drink devoid of high content of quercetin (e.g. apple and onions), rosemary, turmeric, Holy basil, wasabi, broccoli seeds, and licorice thought the duration of the trial. * Individual is able and willing to provide written informed consent and confidentiality agreement.

Exclusion criteria

* Use of dietary supplements within one week of DAy 1. Supplements include any vitamins, minerals, and herbal products, including herbal drink. * Presence of, or clinical significant history of, cancer, cardiovascular, endocrine, kidney, liver, lung, gastrointestinal, metabolic disorder, absorption disorder such as Celiae or Crohn's disease and/or any other chronic health condition such as diabetes identified from the finding of the interview. * Presence of cardiovascular disease and hypertension with inconsistent medication regimen, unstable conditions, and without proper physician's supervision identified from the findings fo the interview. * Individual who use medicines such as statins (e.g. simvastatin, fluvastatin), NSAIDS including aspirin, nitric oxide \*eNOS) activators or inhibitors (e.g. selegiline, Viagra), and angiotensin II receptor blocker (e.g. Telmisartan (blood pressure)), and take any of these medications within 10 hours prior to the blood and urine sample collection. * Individuals who eat spicy food (e.g. capsaicin from chili pepper) and drink coffee and tea including herbal teas within 10 hours prior to the blood and urine sample collection. * Participation in another clinical trial within 30 days of enrollment into the study. * History of current abuse of nicotine, drugs or alcohol, or intake \>3 alcoholic beverages per day * Have known allergy to the ingredients in the tested samples such as quercetin, rosemary, turmeric, Holy basil, wasabi, broccoli seeds, and licorice. * Any condition that the principal Investigator believes amy put the subject under risk.

Design outcomes

Primary

MeasureTime frameDescription
Change in urine 8-isoprostaneDay 1, 15Change in antioxidant biomarker from baseline to day 15

Secondary

MeasureTime frameDescription
Change in erythrocyte Superoxide Dismutase1, 15Change in antioxidant biomarker from baseline to day 15
Change in plasma malondialdehydeDay 1, 15Change in antioxidant biomarker from baseline to day 15
Plasma hemoxygenase-1Day 1, 15Change in antioxidant biomarker from baseline to day 15
Erythrocyte glutathione peroxidaseDay 1, 15Change in antioxidant biomarker from baseline to day 15

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026